1.Efficacy and safety of esomeprazole enteric coated capsules in the treatment of duodenal ulcer
Song ZHU ; Haigang ZHOU ; Zongshuang LI
Chinese Journal of Biochemical Pharmaceutics 2017;37(6):335-336
Objective To observe the efficacy and safety of esomeprazole enteric coated capsules in the treatment of duodenal ulcer.Methods52 cases of duodenal ulcer were selected and randomly divided into the observation group and the control group, 26 cases in each group.The control group was treated with omeprazole, the observation group was treated with esomeprazole enteric coated capsules, and the therapeutic effects of the two groups were evaluated.ResultsThe eradication rate of Helicobacter pylori in the observation group was 96.15% (25/26),which was significantly higher than the control group 80.76%(21/26)(P<0.05), and the clinical efficacy was better, had no serious adverse reactions.ConclusionEsomeprazole enteric coated capsules, can effectively help improve the symptoms of patients with duodenal ulcer, remove the Helicobacter pylori, and no serious adverse reaction, high safety.
2.Papillon-Lefèvre syndrome: a case report and mutation analysis of the cathepsin C gene
Zhiming LI ; Jingjing LIU ; Haigang ZHU ; Xueqi ZHANG ; Xiaohua LIN ; Bingxu LI ; Yunsheng XU
Chinese Journal of Dermatology 2015;48(11):767-769
Objective To analyze mutations in the cathepsin C (CTSC) gene in a patient with Papillon-Lefèvre syndrome (PLS).Methods Clinical data were collected from a patient with PLS.Two milliliters of venous blood samples were obtained from the patient,his parents and 100 unrelated healthy controls separately.DNA was extracted from these blood samples,and PCR was performed to amplify all the 7 exons of the CTSC gene followed by direct DNA sequencing.Results Two heterozygous mutations were observed in the CTSC gene of the patient.One was a novel mutation c.824C > T at position 824 in the exon 6,which resulted in a substitution of ACC (threonine) by ATC (isoleucine) at codon 275 (p.T275I).The other one was the mutation c.1040A > G at position 1040 in the exon 7,causing the substitution of TAT (tyrosine) by TGT (cysteine) at codon 347 (p.Y347C).His father and mother carried the heterozygous mutation c.824C > T and c.1040A > G respectively.Neither of the two mutations was observed in the 100 healthy controls.Conclusions CTSC mutations are responsible for the clinical phenotype of PLS.Identification of the c.824C > T mutation extends the spectrum of mutations in the CTSC gene and provides a basis for genetic diagnosis of PLS.